Terms: = Leukemia AND WHSC1, 7468, O96028, WHS, TRX5, REIIBP, NSD2, MMSET, MGC176638, KIAA1090, FLJ23286
57 results:
1. Discovery of LLC0424 as a Potent and Selective
Liu L; Parolia A; Liu Y; Hou C; He T; Qiao Y; Eyunni S; Luo J; Li C; Wang Y; Zhou F; Huang W; Ren X; Wang Z; Chinnaiyan AM; Ding K
J Med Chem; 2024 May; 67(9):6938-6951. PubMed ID: 38687638
[TBL] [Abstract] [Full Text] [Related]
2. The T1150A cancer mutant of the protein lysine dimethyltransferase nsd2 can introduce H3K36 trimethylation.
Khella MS; Schnee P; Weirich S; Bui T; Bröhm A; Bashtrykov P; Pleiss J; Jeltsch A
J Biol Chem; 2023 Jun; 299(6):104796. PubMed ID: 37150325
[TBL] [Abstract] [Full Text] [Related]
3. nsd2 E1099K drives relapse in pediatric acute lymphoblastic leukemia by disrupting 3D chromatin organization.
Narang S; Evensen NA; Saliba J; Pierro J; Loh ML; Brown PA; Kolekar P; Mulder H; Shao Y; Easton J; Ma X; Tsirigos A; Carroll WL
Genome Biol; 2023 Apr; 24(1):64. PubMed ID: 37016431
[TBL] [Abstract] [Full Text] [Related]
4. MORF and MOZ acetyltransferases target unmethylated CpG islands through the winged helix domain.
Becht DC; Klein BJ; Kanai A; Jang SM; Cox KL; Zhou BR; Phanor SK; Zhang Y; Chen RW; Ebmeier CC; Lachance C; Galloy M; Fradet-Turcotte A; Bulyk ML; Bai Y; Poirier MG; Côté J; Yokoyama A; Kutateladze TG
Nat Commun; 2023 Feb; 14(1):697. PubMed ID: 36754959
[TBL] [Abstract] [Full Text] [Related]
5. nsd2 as a Promising Target in Hematological Disorders.
Azagra A; Cobaleda C
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232375
[TBL] [Abstract] [Full Text] [Related]
6. The constitutional gain-of-function variant p.Glu1099Lys in nsd2 is associated with a novel syndrome.
Popp B; Brugger M; Poschmann S; Bartolomaeus T; Radtke M; Hentschel J; Di Donato N; Rump A; Gburek-Augustat J; Graf E; Wagner M; Sorge I; Lemke JR; Meitinger T; Abou Jamra R; Strehlow V; Brunet T
Clin Genet; 2023 Feb; 103(2):226-230. PubMed ID: 36189577
[TBL] [Abstract] [Full Text] [Related]
7. Glucocorticoid receptor gene mutations confer glucocorticoid resistance in B-cell precursor acute lymphoblastic leukemia.
Tamai M; Kasai S; Akahane K; Thu TN; Kagami K; Komatsu C; Abe M; Watanabe A; Goi K; Miyake K; Inaba T; Takita J; Goto H; Minegishi M; Iwamoto S; Sugita K; Inukai T
J Steroid Biochem Mol Biol; 2022 Apr; 218():106068. PubMed ID: 35124168
[TBL] [Abstract] [Full Text] [Related]
8. Clonal dynamics in pediatric B-cell precursor acute lymphoblastic leukemia with very early relapse.
Antić Ž; Yu J; Bornhauser BC; Lelieveld SH; van der Ham CG; van Reijmersdal SV; Morgado L; Elitzur S; Bourquin JP; Cazzaniga G; Eckert C; Camós M; Sutton R; Cavé H; Moorman AV; Sonneveld E; Geurts van Kessel A; van Leeuwen FN; Hoogerbrugge PM; Waanders E; Kuiper RP
Pediatr Blood Cancer; 2022 Jan; 69(1):e29361. PubMed ID: 34597466
[TBL] [Abstract] [Full Text] [Related]
9. PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by
Li J; Hlavka-Zhang J; Shrimp JH; Piper C; Dupéré-Richér D; Roth JS; Jing D; Casellas Román HL; Troche C; Swaroop A; Kulis M; Oyer JA; Will CM; Shen M; Riva A; Bennett RL; Ferrando AA; Hall MD; Lock RB; Licht JD
Cancer Discov; 2022 Jan; 12(1):186-203. PubMed ID: 34417224
[TBL] [Abstract] [Full Text] [Related]
10. Plasma cells expression from smouldering myeloma to myeloma reveals the importance of the PRC2 complex, cell cycle progression, and the divergent evolutionary pathways within the different molecular subgroups.
Boyle EM; Rosenthal A; Ghamlouch H; Wang Y; Farmer P; Rutherford M; Ashby C; Bauer M; Johnson SK; Wardell CP; Wang Y; Hoering A; Schinke C; Thanendrarajan S; Zangari M; Barlogie B; Dhodapkar MV; Davies FE; Morgan GJ; van Rhee F; Walker BA
Leukemia; 2022 Feb; 36(2):591-595. PubMed ID: 34365473
[TBL] [Abstract] [Full Text] [Related]
11. 5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (nsd2) inhibitors for the treatment of multiple myeloma.
Wang S; Yang H; Su M; Lian F; Cong Z; Wei R; Zhou Y; Li X; Zheng X; Li C; Fu X; Han X; Shi Q; Li C; Zhang N; Geng M; Liu H; Li J; Huang X; Wang J
Eur J Med Chem; 2021 Oct; 222():113592. PubMed ID: 34147909
[TBL] [Abstract] [Full Text] [Related]
12. RNA-sequencing data-driven dissection of human plasma cell differentiation reveals new potential transcription regulators.
Kassambara A; Herviou L; Ovejero S; Jourdan M; Thibaut C; Vikova V; Pasero P; Elemento O; Moreaux J
Leukemia; 2021 May; 35(5):1451-1462. PubMed ID: 33824465
[TBL] [Abstract] [Full Text] [Related]
13. Discovery of Small-Molecule Antagonists of the PWWP Domain of nsd2.
Ferreira de Freitas R; Liu Y; Szewczyk MM; Mehta N; Li F; McLeod D; Zepeda-Velázquez C; Dilworth D; Hanley RP; Gibson E; Brown PJ; Al-Awar R; James LI; Arrowsmith CH; Barsyte-Lovejoy D; Min J; Vedadi M; Schapira M; Allali-Hassani A
J Med Chem; 2021 Feb; 64(3):1584-1592. PubMed ID: 33522809
[TBL] [Abstract] [Full Text] [Related]
14. Multiclonal complexity of pediatric acute lymphoblastic leukemia and the prognostic relevance of subclonal mutations.
Antić Ž; Yu J; Van Reijmersdal SV; Van Dijk A; Dekker L; Segerink WH; Sonneveld E; Fiocco M; Pieters R; Hoogerbrugge PM; Van Leeuwen FN; Van Kessel AG; Waanders E; Kuiper RP
Haematologica; 2021 Dec; 106(12):3046-3055. PubMed ID: 33147938
[TBL] [Abstract] [Full Text] [Related]
15. Proteosomal degradation of nsd2 by BRCA1 promotes leukemia cell differentiation.
Park JW; Kang JY; Hahm JY; Kim HJ; Seo SB
Commun Biol; 2020 Aug; 3(1):462. PubMed ID: 32826945
[TBL] [Abstract] [Full Text] [Related]
16. De novo damaging variants associated with congenital heart diseases contribute to the connectome.
Ji W; Ferdman D; Copel J; Scheinost D; Shabanova V; Brueckner M; Khokha MK; Ment LR
Sci Rep; 2020 Apr; 10(1):7046. PubMed ID: 32341405
[TBL] [Abstract] [Full Text] [Related]
17. The nsd2 p.E1099K Mutation Is Enriched at Relapse and Confers Drug Resistance in a Cell Context-Dependent Manner in Pediatric Acute Lymphoblastic leukemia.
Pierro J; Saliba J; Narang S; Sethia G; Saint Fleur-Lominy S; Chowdhury A; Qualls A; Fay H; Kilberg HL; Moriyama T; Fuller TJ; Teachey DT; Schmiegelow K; Yang JJ; Loh ML; Brown PA; Zhang J; Ma X; Tsirigos A; Evensen NA; Carroll WL
Mol Cancer Res; 2020 Aug; 18(8):1153-1165. PubMed ID: 32332049
[TBL] [Abstract] [Full Text] [Related]
18. Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer.
Lin KH; Rutter JC; Xie A; Pardieu B; Winn ET; Bello RD; Forget A; Itzykson R; Ahn YR; Dai Z; Sobhan RT; Anderson GR; Singleton KR; Decker AE; Winter PS; Locasale JW; Crawford L; Puissant A; Wood KC
Nat Genet; 2020 Apr; 52(4):408-417. PubMed ID: 32203462
[TBL] [Abstract] [Full Text] [Related]
19. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.
Jain P; Zhang S; Kanagal-Shamanna R; Ok CY; Nomie K; Gonzalez GN; Gonzalez-Pagan O; Hill HA; Lee HJ; Fayad L; Westin J; Nastoupil L; Hagemeister F; Chen W; Oriabure O; Badillo M; Jiang C; Yixin Y; Li S; Tang G; Yin CC; Patel KP; Medeiros LJ; Nair R; Ahmed S; Iyer SP; Thirumurthi S; Champlin R; Xu G; Tinsu P; Santos D; Wang R; Han G; Zhang J; Song X; Neelapu S; Romaguera J; Futreal A; Flowers C; Fowler N; Wang L; Wang ML
Blood Adv; 2020 Mar; 4(6):1038-1050. PubMed ID: 32191807
[TBL] [Abstract] [Full Text] [Related]
20. Multiple Myeloma DREAM Challenge reveals epigenetic regulator PHF19 as marker of aggressive disease.
Mason MJ; Schinke C; Eng CLP; Towfic F; Gruber F; Dervan A; White BS; Pratapa A; Guan Y; Chen H; Cui Y; Li B; Yu T; Chaibub Neto E; Mavrommatis K; Ortiz M; Lyzogubov V; Bisht K; Dai HY; Schmitz F; Flynt E; Dan Rozelle ; Danziger SA; Ratushny A; ; Dalton WS; Goldschmidt H; Avet-Loiseau H; Samur M; Hayete B; Sonneveld P; Shain KH; Munshi N; Auclair D; Hose D; Morgan G; Trotter M; Bassett D; Goke J; Walker BA; Thakurta A; Guinney J
Leukemia; 2020 Jul; 34(7):1866-1874. PubMed ID: 32060406
[TBL] [Abstract] [Full Text] [Related]
[Next]
